Table 2.

Relative risk of conversion to an elevated PSA between baseline and year 4 using 4 and 6 ng/mL cutoff points

Cut point (ng/mL)Placebo (n = 263), n cases (%)Calcium (n = 279), n cases (%)Risk ratio (95% CI)
>421 (8)14 (5)0.63 (0.33-1.21)
>613 (5)10 (4)0.73 (0.32-1.63)
  • NOTE: PSA concentration determined at both baseline and year 4 for 263 men assigned to the placebo group and 279 to the calcium group.